223 related articles for article (PubMed ID: 24252853)
1. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
2. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
[TBL] [Abstract][Full Text] [Related]
5. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
9. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
10. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
11. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
13. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
14. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
16. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
17. M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells.
Gray Z; Tabarraei A; Moradi A; Kalani MR
Mol Biol Rep; 2019 Jun; 46(3):3371-3379. PubMed ID: 31006094
[TBL] [Abstract][Full Text] [Related]
18. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus as a treatment for colorectal cancer.
Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
